Direct Meds vs Gala Health
Two GLP-1 desks, one scoreboard. We put Direct Meds and Gala Health head-to-head on the published Brief Score — the same six factors, scored the same way.
Direct Meds
FDA warning letter, September 2025 — issued to directmeds.com, Inc. dba DirectMeds. See the FDA's warning letter database.
The verdict
Too close to call on the Brief Score.
Direct Meds and Gala Health are level at 82/100. The scores won't separate them, so the pick comes down to fit: Direct Meds for readers who want a needle-free oral or sublingual route on either molecule and an all-inclusive price with no separate membership — and who are comfortable that the figures are company-stated rather than checkout-verified. Gala Health for readers ready to commit to a year of compounded tirzepatide up front, who want it available in all 50 states and like knowing a brand-name ozempic route exists if they ever switch — and who value a menopause/hrt program alongside the glp-1.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Direct Meds | Gala Health | |
|---|---|---|
| Brief Score | 82/100 (B−) | 82/100 (B−) |
| Semaglutide | $249/mo sublingual · $297/mo injectable — both billed monthly on a 3-month minimum commitment | Compounded semaglutide is included in the same From $179/mo yearly-subscription plan; brand-name Ozempic from $1,299/mo cash |
| Tirzepatide | $299/mo sublingual · $399/mo injectable — both billed monthly on a 3-month minimum commitment | From $179/mo only on the yearly subscription; $199/mo on the 3-month plan (all doses included) |
| Coverage | Not publicly listed | All 50 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Yes | Injection only |
| On the tracker | Stableprice stable | Stableprice stable |
Direct Meds: Company-stated rates unchanged this cycle — but we price these off the provider's own listings, not a live-verified checkout, so treat them as indicative.
Gala Health: Headline compounded-tirz rate unchanged this cycle, but it is a yearly-subscription price — the shortest published plan is three months at $199/mo, and no month-to-month rate exists.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
One price on both molecules that does not climb as you titrate — but the headline $99 and $149 are annual-plan rates, paid in full up front.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.